Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal
failure and hemoglobin< 10 g/dL. Background Left ventricular hypertrophy (LVH) frequently …

Myocardial effects of recombinant human erythropoietin (rhEPO) treatment were
prospectively investigated in 15 hemodialysis (HD) patients with severe anemia (hematocrit …

Objective Left ventricular hypertrophy (LVH) has been identified as an independent risk
factor for mortality in patients with chronic renal failure (CRF) and anemia has been …

The substitution of recombinant human erythropoietin (rhEPO) in chronic hemodialysis
patients is often associated with the development of severe hypertension. In the present …

The course of left ventricular hypertrophy was investigated in anemic hemodialysis patients
treated with recombinant human erythropoietin (r-huEPO). 12 patients, aged 60.8±9.9 years …

The results of anemia correction by recombinant human erythropoietin (rHuEPO) therapy
with regard to cardiac function and left ventricular hypertrophy in dialysis patients are …

Long-term myocardial effects of recombinant human erythropoietin (rhEPO) therapy were
investigated in nine hemodialysis (HD) patients greater than 60 years of age …

Patients with end-stage renal disease (ESRD) have much higher rates of cardiovascular
disease than the healthy population. Left ventricular hypertrophy (LVH), in particular, is …

Erythropoietin Therapy and Left Ventricular Mass Index in CK... : Clinical Journal of the
American Society of Nephrology Erythropoietin Therapy and Left Ventricular Mass Index in CKD …

Treatment with recombinant human erythropoietin (rHuEPO) has solved the problem of
anemia in patients on dialysis. However, its application to predialysis patients has raised …